74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Vericel Corp
Closed
Sector Healthcare
51.96 -3.85
Overview
Share price change
24h
Min
51.68
Max
54.47
Income | 3.8M -901K |
|---|---|
Sales | 5.2M 58M |
P/E Sector Avg | 722.25 73.394 |
EPS | -0.02 |
Profit margin | -1.556 |
Employees | 314 |
EBITDA | 3.8M 579K |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +14.92 upside |
Next Earnings | 27 Feb 2025 |
|---|
Market Cap | 2.9B |
|---|---|
Previous open | 55.81 |
Previous close | 51.96 |
News Sentiment
By Acuity
100%
0%
380 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Vericel Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vericel Corp Forecast
Price Target
By TipRanks
14.92% upside
12 Months Forecast
Average 66.4 USD 14.92%
High 72 USD
Low 60 USD
Based on 6 Wall Street analysts offering 12 month price targets forVericel Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
